Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00526591 · ClinicalTrials.gov registry record · Phase 2
Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer
A Phase 2 study, sponsored by Jorge A. Garcia, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00526591: Clinical Trial Phase 2 study, sponsored by Jorge A. Garcia, MD.
NCT00526591 is a Phase 2 study that was terminated before completion, run by Jorge A. Garcia, MD. The registered enrollment target is 17 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00526591, a Phase 2 study, was terminated before completion, sponsored by Jorge A. Garcia, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving everolimus before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This randomized phase II trial is studying the side effects and how well everolimus works in treating patients with newly diagnosed localized prostate cancer.
Primary Outcome
Specimens are fixed in formalin for 24 hours.Specimens are the cut at 3 mm intervals perpendicular to the rectal surface and the sections are examined grossly and microscopically on routine Hematoxylin and Eosin stain (H\&E) (pathologic complete response or P0) will be defined as responders.
Interventions
- DRUG Everolimus
- PROCEDURE conventional surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2007-09 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Why NCT00526591 stopped before completion
NCT00526591 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT00526591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00526591 about?
NCT00526591 is a clinical study titled "Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer". RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving everolimus before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This randomized phase II trial is studying the side ...
What is the current status of trial NCT00526591?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2007-09. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00526591?
The interventions under investigation include: Everolimus (DRUG), conventional surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00526591?
This trial is sponsored by Jorge A. Garcia, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00526591's enrollment target sits among peer trials
17 1903rd of 2000 higher than 93 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia